On Demand Webinars Page

Browse our free, educational webinars— covering topics including clinical pharmacology, pharmacometrics, PBPK modeling and simulation, regulatory writing, real world evidence, and market access, all available on-demand.

Genentech

PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib Case Study

Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating advanced melanoma. As in the best practice case of ibrutinib, we generally perform physiologically-based pharmacokinetic (PBPK) simulations with model verification based on CYP3A4 strong inhibitor...

Alkermes

Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification Case Study

Aripiprazole lauroxil (Aristada®) was approved by the FDA for treating schizophrenia in adults in October 2015 at monthly and 6-week dosing options. Although aripiprazole was not a new drug, Aristada was a new, long-acting injectable formulation to combat this challenging...

Novartis

Simcyp’s Age-Defining Feature Facilitates Everolimus Dosing in Neonates Case Study

Everolimus (Afinitor®) was recently approved as adjunctive therapy for tuberous sclerosis complex (TSC)-associated partial seizures in ages 2 and older. Unlike many other therapies for treating TSC-associated seizures, everolimus addresses the underlying pathophysiology of TSC. As TSC-associated seizures can also...